Humacyte chief commercial officer purchases $9,999 in common stock

In a recent transaction, William John Scheessele, the Chief Commercial Officer of Humacyte, Inc. (NASDAQ:HUMA), acquired 6,493 shares of the company’s common stock. This purchase, executed on April 14, 2025, was made at a price of $1.54 per share, totaling approximately $9,999. The timing is notable, as InvestingPro data shows the stock has gained nearly 30% over the past week, though it remains down about 74% over the past six months.

Following this transaction, Scheessele’s direct ownership of Humacyte’s common stock increased to 22,018 shares. The acquisition reflects a continued confidence in the company, which operates in the biological products industry, excluding diagnostic substances. Humacyte is headquartered in Durham, North Carolina. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 2.4, though it faces near-term challenges. Analysts have set price targets ranging from $3 to $25, suggesting potential upside opportunities. For deeper insights into Humacyte’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Humacyte reported a fourth-quarter loss of $0.16 per share, which was better than analysts’ expectations of a $0.25 per share loss. Despite this, the company generated no revenue during the quarter, consistent with the previous year’s results. The lack of revenue comes after the FDA approved Humacyte’s vascular graft product, Symvess, in December, with commercial shipments beginning in late February. CEO Laura Niklason stated that 34 hospitals have started the approval process to purchase Symvess, with three hospitals completing approvals.

Benchmark analysts maintained a Buy rating on Humacyte with a $17 price target, highlighting the company’s progress with Symvess distribution and potential market capture for various surgical procedures. In contrast, BTIG analyst Ryan Zimmerman also kept a Buy rating but lowered the price target from $10 to $8, citing early commercial traction as a positive sign. Humacyte ended 2024 with $95.3 million in cash and raised an additional $46.6 million through a public stock offering in March 2025.

The company plans to file an Investigational New Drug application in 2025 for coronary artery bypass grafting and a supplemental application in late 2026 to expand Symvess’ uses to include dialysis access. Humacyte’s increased net loss of $148.7 million for the full year 2024 was primarily due to higher research and development expenses and preparation costs for the commercial launch of Symvess. Despite financial challenges, analysts remain optimistic about Humacyte’s future potential in regenerative medicine.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.